| Bioactivity | TN14003 is a CXCR4 inhibitor. TN14003 has antitumor activity[1]. |
| In Vivo | TN14003 (7.5 mg/kg, 腹腔注射, 每周连续 5 天) 通过降低血管生成和肌成纤维细胞含量抑制 HER2肿瘤生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 368874-31-1 |
| Sequence | Arg-Arg-{Ala-(2-Naph)}-Cys-Tyr-{Cit}-Lys-Lys-Pro-Tyr-Arg-{Cit}-Cys-Arg-NH2 (Disulfide bridge: Cys4-Cys13) |
| Shortening | RR-{Ala-(2-Naph)}CY-{Cit}-KKPYR-{Cit}-CR-NH2 (Disulfide bridge: Cys4-Cys13) |
| Formula | C90H141N33O18S2 |
| Molar Mass | 2037.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lefort S, et al. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients. Oncogene. 2017 Mar 2;36(9):1211-1222. |